BioPorto Advances Adult AKI Test Validation with U.S. Patient Enrollment — BioPorto A/S

Event summary

BioPorto initiated patient enrollment for the ProNephro AKI U.S. Adult Urine NGAL Validation Study on September 16, 2026.
The study aims to validate the clinical performance of ProNephro AKI (NGAL) for risk assessment of moderate to severe Acute Kidney Injury (AKI) in adult ICU patients.
Approximately 900 patients will be enrolled across multiple U.S. clinical sites, including Massachusetts General Hospital.
ProPharma continues as the Clinical Research Organization for this study, following its involvement in the preceding AKI cut-off study.

The big picture

BioPorto's initiation of the ProNephro AKI U.S. Adult Urine NGAL Validation Study marks a critical step in expanding its diagnostic capabilities beyond the pediatric market. The study's success could position BioPorto as a key player in the adult AKI diagnostics space, addressing a significant unmet medical need. The collaboration with ProPharma and the involvement of leading U.S. hospitals underscore the strategic importance of this clinical validation effort.

What we're watching

Regulatory Pathway: The pace at which BioPorto can secure FDA approval for the adult indication will determine its market expansion timeline.
Clinical Validation: Whether the study results will support the clinical evidence needed for a potential adult indication in the United States.
Market Dynamics: How BioPorto's expansion into the adult AKI market will affect its competitive positioning against existing diagnostic solutions.